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Introduction: PRONOUNCE compared the efficacy and safety of 
pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with 
paclitaxel+carboplatin+bevacizumab followed by bevacizumab 
(Pac+Cb+Bev) in patients with advanced nonsquamous non–small-
cell lung cancer (NSCLC).
Methods: Patients ≥18 years of age with stage IV nonsquamous 
NSCLC (American Joint Committee on Cancer v7.0), and Eastern 
Cooperative Oncology Group performance status 0/1 were ran-
domized (1:1) to four cycles of induction Pem+Cb (pemetrexed, 
500 mg/m2, carboplatin, area under the curve = 6) followed by Pem 
maintenance or Pac+Cb+Bev (paclitaxel, 200 mg/m2, carboplatin, 
area under the curve = 6, and bevacizumab, 15 mg/kg) followed 
by Bev maintenance in the absence of progressive disease or dis-
continuation. The primary objective was progression-free survival 
(PFS) without grade 4 toxicity (G4PFS). Secondary end points 
were PFS, overall survival (OS), overall response rate (ORR), dis-
ease control rate (DCR), and safety. Resource utilization was also 
assessed.
Results: Baseline characteristics of the patients randomized to 
Pem+Cb (N = 182) and Pac+Cb+Bev (N = 179) were well bal-
anced between the arms. Median (months) G4PFS was 3.91 for 
Pem+Cb and 2.86 for Pac+Cb+Bev (hazard ratio = 0.85, 90% con-
fidence interval, 0.7–1.04; p = 0.176); PFS, OS, ORR, or DCR 
did not differ significantly between the arms. Significantly more 
drug-related grade 3/4 anemia (18.7% versus 5.4%) and throm-
bocytopenia (24.0% versus 9.6%) were reported for Pem+Cb. 
Significantly more grade 3/4 neutropenia (48.8% versus 24.6%), 
grade 1/2 alopecia (28.3% versus 8.2%), and grade 1/2 sensory 
neuropathy were reported for Pac+Cb+Bev. Number of hospi-
talizations and overall length of stay did not differ significantly 
between the arms.
Conclusions: Pem+Cb did not produce significantly better G4PFS 
compared with Pac+Cb+Bev. Pem+Cb was not superior in PFS, OS, 
ORR, or DCR compared with Pac+Cb+Bev. Both regimens were 
well tolerated, although, toxicity profiles differed.
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Lung cancer is the leading cause of cancer mortality in the United States accounting for more than a quarter of cancer 
deaths for both men and women.1 Non–small-cell lung cancer 
(NSCLC) accounts for ~85% of the lung cancer histologies in 
the United States, and 70% of the patients with NSCLC pres-
ent with inoperable, locally advanced (stage III) or metastatic 
(stage IV) disease.2
Patients with stage IV NSCLC and Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) 0 or 1 ben-
efit in survival and quality of life from standard platinum dou-
blet chemotherapy.3–6 No randomized trial has demonstrated 
superiority of one platinum-based doublet over another for 
unselected patients.7–10 The three-drug regimen of carboplatin/
paclitaxel/bevacizumab induction followed by bevacizumab 
maintenance was approved for nonsquamous NSCLC based 
on the well-known ECOG 4599 clinical trial.11 This regimen 
has been adopted as the new ECOG standard for patients eli-
gible to receive bevacizumab.11 Currently in the United States, 
less than half of all the new lung cancer diagnoses are made in 
patients who would have met the eligibility criteria for ECOG 
4599 and it is usually estimated that no more than a third of 
the lung cancer patients in the United States are treated with 
this regimen.12
Pemetrexed is a multitargeted antifolate approved for 
first-line, second-line, and maintenance treatment of nonsqua-
mous NSCLC.13–16 A prespecified analysis of a large phase III 
first-line study showed that pemetrexed/cisplatin produced 
superior overall survival (OS) to gemcitabine/cisplatin for 
patients with nonsquamous NSCLC.14,17 In first-line mainte-
nance, pemetrexed was superior to placebo for OS in large 
phase III studies after initial chemotherapy with pemetrexed 
or taxane-based regimens.15–17 Superior OS with pemetrexed 
versus docetaxel also was confirmed in a post hoc analysis 
of second-line study data for nonsquamous histologies.18 In 
the US, cisplatin doublets are less often used than carboplatin 
doublets, and although it has not been directly compared in a 
phase III trial, pemetrexed/carboplatin is more often used in 
clinical practice in the US.19,20
PRONOUNCE was designed to assess the efficacy 
and safety of pemetrexed+carboplatin followed by peme-
trexed maintenance (Pem+Cb) versus paclitaxel+carbo-
platin+bevacizumab followed by bevacizumab maintenance 
(Pac+Cb+Bev) in patients with advanced nonsquamous 
NSCLC. PRONOUNCE was designed as a supportive study 
for the PointBreak study and has similar patient eligibility and 
monitoring.21
A maximum of four cycles of induction therapy was 
chosen based on recent reviews and meta-analyses confirm-
ing four cycles as the optimal duration of first-line platinum 
combination therapy.22–25 G4PFS defined by the Common 
Terminology Criteria for Adverse Events (CTCAE) is a 
composite end point that includes both efficacy and safety 
outcomes. The G4PFS primary end point is reasonable for 
clinical trials comparing regimens where efficacy is likely to 
be similar, making a less toxic regimen clinically relevant, 
particularly in the noncurative setting.21,26 The hypothesis for 
PRONOUNCE trial was that Pem+Cb would be superior to 
Pac+Cb+Bev for G4PFS.
MATERIALS AND METHODS
Eligibility Criteria
Chemotherapy naïve adults (≥18 years of age) with 
histologically or cytologically confirmed stage IV (American 
Joint Committee on Cancer, version 7) nonsquamous NSCLC, 
ECOG PS 0 or 1, measurable disease by Response Evaluation 
Criteria in Solid Tumors,27 and adequate organ function 
were eligible. Stable, treated brain metastases were allowed. 
Patients were required to be eligible for both pemetrexed and 
bevacizumab. Women of childbearing potential were required 
to have a negative pregnancy test, and all the patients for 
whom pregnancy was a risk were required to use effective 
contraception. The patients were excluded for any contraindi-
cations for pemetrexed or bevacizumab or for general radio-
therapy within 2 weeks, stereotactic brain radiotherapy within 
7 days, major surgery within 28 days, minor surgery within 7 
days, neurosurgical resection or brain biopsy within 3 months 
before day 1, cycle 1. Additional exclusions included the use 
of an investigational agent within 30 days of randomization 
and any serious concomitant disorder that could compromise 
the ability to adhere to the protocol.
The study protocol was approved by ethical review 
boards at each of the participating investigational sites and 
was conducted in accordance with the Declaration of Helsinki 
and Good Clinical Practice guidelines. All the patients signed 
written informed consent before the initiation of any study 
interventions.
Study Design, Treatment, and End points
In this multicenter, randomized, open-label, US-only 
phase III trial, the eligible patients with nonsquamous NSCLC 
were randomized in a 1:1 ratio to Pem+Cb or Pac+Cb+Bev by 
standard protocols including B12 and folate supplementation 
for pemetrexed and dexamethasone premedication for both 
the arms. Patients in the Pac+Cb+Bev arm received additional 
standard prophylaxis against allergic reactions according to 
the paclitaxel label. Randomization was stratified for disease 
stage (M1a versus M1b), ECOG PS, and sex. After four cycles 
of induction therapy every 21 days, maintenance continued 
until disease progression or intolerance. Planned chemo-
therapy doses were pemetrexed 500 mg/m2; carboplatin, area 
under the curve = 6, (as of December 31, 2010, maximum 
possible dose of 900 mg), paclitaxel 200 mg/m2; bevacizumab 
15 mg/kg.
Any required dose reductions, per label indication for 
each drug or regimen, were maintained for the remainder of 
the study per CTCAE.28 A maximum of two dose reductions 
were permitted before the patients were discontinued from the 
study therapy. Bevacizumab doses were not reduced due to 
toxicity but bevacizumab was interrupted for any unresolved 
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adverse events (AEs). Upon resolution of select AEs, beva-
cizumab was resumed at the full dose at the next cycle. The 
maximum allowable length of any study treatment interrup-
tion was 42 days.
The primary objective of this trial was to compare 
G4PFS between the two treatment arms in the intent-to-
treat (ITT) population.29 G4PFS was measured from the date 
of randomization to the earliest occurrence of the first of 
grade 4 AEs, disease progression, or death from any cause, 
regardless of whether or not the event leads to discontinua-
tion. Secondary end points included PFS (gated secondary 
end point), OS, overall response rate (ORR), disease control 
rate (DCR = complete response + partial response + stable 
disease), and safety. Associated resource use data were also 
collected.
If a patient discontinued study therapy without disease 
progression, the tumor measurements were performed at 30 
days and subsequently every 6 weeks (± 2 weeks) until objec-
tive disease progression. Thereafter, the patient was followed 
every 90 days (± 14 days) for survival.
As a post hoc analysis of the AEs that are important to 
patients, we have reviewed the symptoms described by Dubey 
et al.30 in their analysis of data from a questionnaire answered 
by 464 patients with lung cancer (registered in the Alliance 
for Lung Cancer Advocacy, Support, and Education database 
from 2000 to 2002).
Statistical Plan and Analyses
The study was powered for G4PFS; assuming a hazard 
ratio (HR) of 0.75, approximately 360 randomized patients 
(180 per arm) were needed for 80% power to detect superior-
ity of the Pem+Cb arm over the Pac+Cb+Bev arm with a two-
sided type I error of 0.10. PFS (gated end point) and OS were 
key secondary end points. Efficacy data were analyzed by ITT 
using all randomized patients, and safety data were evaluated 
using CTCAE v3 for patients who received ≥ 1 dose of study 
treatment (grouped as treated).
All other tests of treatment effects were conducted at 
a two-sided alpha level of 0.05 and all confidence intervals 
(CIs) were given at a two-sided 95% level, unless otherwise 
specified.
For the time-to-event end points, including G4PFS, PFS, 
and OS, Kaplan-Meier estimates and (nonstratified) log-rank 
test were employed. Cox regression model (non-stratified) was 
used to estimate the treatment HR. Fisher’s exact tests were 
used to compare differences in the ORR and DCR between 
the two treatment arms. The safety analysis included the maxi-
mum grade CTCAEs of laboratory and nonlaboratory events, 
serious AEs, treatment-emergent AEs, hospitalizations, trans-
fusions, and the use of concomitant medications. Comparisons 
of the incidences of toxicities and resources use between the 
two treatment arms were performed using Fisher’s exact test.
RESULTS
Patient Disposition
A CONSORT diagram depicting the patient enroll-
ment and disposition is presented in Figure 1. A total of 496 
patients were screened from September 2009 to January 2013 
with data cutoff January 31, 2013; 135 patients were excluded 
for eligibility (n = 105), death (n = 3), or subject decision 
(n = 27); and 361 patients were randomized (Pem+Cb = 182; 
Pac+Cb+Bev = 179). Twelve patients in each arm did not 
receive study treatment after randomization, and the most 
common reasons included patient decision, entry crite-
ria exclusion, and AEs. At the time of data cutoff (January 
31, 2013), 352 patients (n = 177 on Pem+Cb; n = 175 on 
Pac+Cab+Bev) had discontinued study therapy, and nine 
patients (n = 5 on Pem+Cb; n = 4 on Pac+Cab+Bev) were 
continuing study therapy.
Patient Baseline Characteristics
Patient baseline demographic and disease-related char-
acteristics (ITT population) are presented in Table 1. Baseline 
Patients Screened, N = 496
Discontinuations, n = 177
Reasons for discontinuation:
Progressive disease, n = 115
Physician/patient decision, n = 30
Adverse events, n = 13
Death, n = 11
Other, n = 8
Patients did not 
receive study
treatment, n = 12
Discontinuations, n = 175
Reasons for discontinuation:
Progressive disease, n = 99
Physician/patient decision, n = 29
Adverse events, n = 31
Death, n = 12
Other, n = 4
Patients did not 
receive study
treatment, n = 12
Patients Randomized, N = 361 
(ITT)
Pemetrexed+Carboplatin,
N = 182
Paclitaxel+Carboplatin+
Bevacizumab, N = 179*
Screen failures, n = 135 
(3 Deaths; 105 Entry criteria 
excluded; 27 Subject decision)
FIGURE 1.  Patient CONSORT flow 
diagram. ITT, Intent-to-treat. *1 
patient randomized to Pac+Cb+Bev 
but received Pem+Cb, analyzed per 
ITT population.
137Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015 Pem/Carbo versus Pac/Carbo/Bev Followed by Maintenance
characteristics were well balanced between the treatment arms. 
Most patients were white (89.2%) with median age of 65.6 
(range, 38.4–86.2) years. No p values were calculated for these 
characteristics between the arms as the data were descriptive.
Treatment
The ITT population included 182 in Pem+Cb and 179 in 
Pac+Cb+Bev. The median number of cycles (defined as 50% 
of the patients stay on study treatment) administered was six 
(range, 1–36+ Pem+Cb and 1–31+ Pac+Cb+Bev). The number 
of patients completing four cycles of treatment were simi-
lar between the two treatment arms: 121 patients (70.8%) in 
Pem+Cb arm and 113 patients (68.1%) in Pac+Cb+Bev arm. 
The mean dose intensities in the safety (treated) population 
were similar for both the arms (%, standard deviation): peme-
trexed 92.3 (10.8) and carboplatin 94.1 (11.1) for the Pem+Cb 
arm; paclitaxel 91.5 (14.9), carboplatin 92.8 (15.5), and beva-
cizumab 93.3 (15.5) for the Pac+Cb+Bev arm.
Efficacy Measures
In the ITT population, 296 G4PFS events occurred with 
152 in Pem+Cb and 144 in Pac+Cb+Bev. Median G4PFS 
was not statistically significantly different between the two 
treatment arms as shown by Kaplan-Meier curves (Fig. 2A). 
For Pem+Cb versus Pac+Cb+Bev, the median G4PFS was 3.91 
versus 2.86 months (HR, 0.85, 90% CI, 0.7–1.04, p = 0.176). 
The median PFS was 4.44 months for Pem+Cb versus 5.49 
months for Pac+Cb+Bev (HR, 1.06; 95% CI, 0.84–1.35; 
p = 0.610) (Fig. 2B). The median OS for Pem+Cb was 10.5 
months versus 11.7 months for Pac+Cb+Bev (HR, 1.07; 95% 
CI, 0.83 to 1.36; p = 0.615) (Fig. 2C). One- and 2-year sur-
vival rates were not significantly different between the arms 
and were 43.7% and 18.0% for Pem+Cb and 48.8% and 
17.6% for Pac+Cb+Bev (Fig. 2C). Response rate and DCR 
were 23.6% and 59.9% for Pem+Cb and 27.4% and 57.0% for 
Pac+Cb+Bev (p = 0.414 and 0.575, respectively) (Fig. 2B).
Additional analysis of which G4PFS event (G4AE, 
progressive disease [PD], or death) occurred first in the ITT 
population is shown in Table 2. A total of 296 G4PFS events 
were reported in both the arms. Among these G4PFS events, 
those occurring first were: 101 (34.1%) G4 AEs; 163 (55.1%) 
PD; 32 (10.8%) deaths. The most common G4PFS toxicities 
observed were neutropenia, thrombocytopenia, and throm-
bosis/embolism (Table 2). The p values for the differences 
between the two treatment arms were not calculated as the 
data were descriptive (Table 2).
A sensitivity analysis was performed to evaluate the 
efficacy outcome for patients who received at least one cycle 
of study treatment (safety population). The efficacy results 
based on safety population are similar to that based on the 
ITT population (data not shown).
The preplanned subgroup analyses are shown as Forest 
plots for G4PFS (Fig. 3A) and for OS (Fig. 3B). The unad-
justed HRs (with 95% CIs) shown in these plots do not favor 
any treatment subgroup.
Safety Measures
Grade 3/4 drug-related toxicities that were signifi-
cantly different between the treatment arms in the safety 
population were (Pem+Cb versus Pac+Cb+Bev): anemia 
(18.7% versus 5.4%, p < 0.001), neutropenia (24.6% versus 
48.8%, p < 0.001), and thrombocytopenia (24.0% versus 
9.6%, p < 0.001). Hemorrhage was numerically higher in the 
Pem+Cb arm (1.2% versus 0.00%), and thrombosis/embolism 
was numerically higher in the Pac+Cb+Bev arm (0.0% versus 
2.4%); these differences did not reach statistical significance. 
Grade 3 and grade 4 drug-related AEs in each treatment arm 
are presented in Table 3.
Drug-related events considered most important to 
patients such as nausea, vomiting, infections, alopecia, and 
sensory neuropathy30 were analyzed post hoc in this study. 
Grade 1 (21.7% versus 7.6%), and 2 (8.4% versus 0.6%), 
sensory neuropathy were significantly more common with 
Pac+Cb+Bev compared with Pem+Cb (P < 0.001). Grade 
1 nausea was significantly (p = 0.003) higher in Pem+Cb 
(29.8%) compared with Pac+Cb+Bev (15.7%). However, 
grade 2 nausea was not significantly different between the two 
arms (17.0% versus 13.3%, p = 0.365). Grade 1 (16.3% versus 
5.8%) and 2 (12.0% versus 2.3%) alopecia were significantly 
more common with Pac+Cb+Bev compared with Pem+Cb 
(p < 0.001). The other nonhematological grade 3/4 events 
TABLE 1.  Patient Baseline Demographic and Disease 
Characteristics of Intent-to-Treat Population
Characteristic
Pem+Cb 
N = 182
n (%)
Pac+Cb+Bev 
N = 179
n (%)
Age, years, median (range) 65.8 (38.4–84.1) 65.4 (41.2–86.2)
  >70 years 59 (32.4) 51 (28.5)
Gender
  Female 77 (42.3) 75 (41.9)
Race/ethnicity
  Whitea 165 (90.7) 157 (87.7)
  African American 11 (6.0) 20 (11.2)
  Asian 4 (2.2) 0 (0.0)
  American Indian 0 (0.0) 2 (1.1)
  Multiple 2 (1.1) 0 (0.0)
ECOG PS
  0 85 (46.7) 84 (46.9)
  1 96 (52.7) 95 (53.1)
Disease stage IV 181 (99.5) 179 (100.0)
  M1a 52 (28.6) 53 (29.6)
Histology
  Adenocarcinoma 152 (83.5) 137 (76.5)
  Large cell 1 (0.5) 9 (5.0)
  Other or indeterminate 28 (15.4) 33 (18.4)
Smoking status
  Ever 164 (90.1) 172 (96.1)
No previously treated brain metastasis 159 (87.4) 147 (82.1)
Some patients had missing values for these characteristics; percentage calculated 
accordingly.
aIncludes four (2.2%) in Pem+Cb and five (2.8%) in Pac+Cb+Bev arm who were 
patients of Hispanic ethnicity.
Bev, bevacizumab; Cb, carboplatin; ECOG, Eastern Cooperative Oncology Group; 
Pac, paclitaxel; Pem, pemetrexed; PS, performance status.
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including fatigue, febrile neutropenia, nausea, and vomiting 
were similar between the treatment arms. For patients with 
G4PFS other than PD as the initial event, the incidence of sub-
sequent PD was 18 of 37 for arm A and 22 of 64 for arm B.
The patients who developed G4AEs during the induction 
phase (one to four cycles) were 33 of 37 (89.2%) in Pem+Cb 
and 60 of 64 (93.6%) in Pac+Cb+Bev and in the maintenance 
phase (> 4 cycles), 4 of 37 (10.8%) in Pem+Cb and 3 of 64 
(4.8%) in Pac+Cb+Bev.
Forty-nine patients died during the study or within 
30 days of discontinuation (Pem+Cb, n = 24 [14.0%]; 
Pac+Cb+Bev, n = 25 [15.1%]). Possible drug-related deaths 
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FIGURE 2. A, Kaplan-Meier plot of primary end 
point G4 progression-free survival, (B), Kaplan-
Meier plot showing the progression-free survival 
in intent-to-treat population, (C), Kaplan-Meier 
plot showing the overall survival in intent-to-treat 
population. Bev, bevacizumab; Cb, carboplatin; 
G4PFS, grade 4 progression-free survival; HR, 
hazard ratio; OS, overall survival; Pac, paclitaxel; 
Pem, pemetrexed; PFS, progression-free survival.
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were one patient (0.6%) in Pem+Cb due to neutropenia 
and two patients (1.2%) in Pac+Cb+Bev due to myocardial 
infarction and pulmonary embolism. Deaths not deemed to 
be related to study drug by the investigator were attributed 
to progression of lung cancer (8.2% versus 12.0%) and AEs 
of other causes (5.3% versus 1.8%) including pneumonia, 
respiratory failure, myocardial infarction, stroke, and renal 
failure in the Pem+Cb arm; and respiratory failure, intracra-
nial bleeding, and nonspecific AEs in the Pac+Cb+Bev arm.
In the safety population, the number of patients with at 
least one hospitalization was not significantly different between 
the treatment arms (Pem+Cb, n = 59 [34.5%]; Pac+Cb+Bev, 
n = 53 [31.9%], p = 0.645). Similarly, the mean (SD) number 
of hospitalized days did not differ between the arms (Pem+Cb, 
8.2 [6.79]; Pac+Cb+Bev, 8.8 [7.33], p = 0.682). Significantly, 
more patients treated with Pem+Cb received at least one red 
blood cell transfusion compared with Pac+Cb+Bev (35.7% 
versus 12.7%, p < 0.001). No differences were observed for 
platelet transfusions between the treatment arms (Pem+Cb, 
5.8% versus Pac+Cb+Bev, 4.2%, p = 0.621).
Use of rescue antiemetics (64.3% in Pem+Cb versus 
60.8% in Pac+Cb+Bev, p = 0.574), analgesics (88.9% in 
Pem+Cb versus 92.2% in Pac+Cb+Bev, p = 0.355), and anti-
biotics (53.2% in Pem+Cb versus 59.0% in Pac+Cb+Bev, 
p = 0.323) did not differ significantly between the treatment 
arms. Use of erythropoetic stimulating agents was significantly 
higher in Pem+Cb (19.9%) compared with Pac+Cb+Bev 
(7.2%) (p < 0.001), whereas the use of granulocyte colony 
stimulating factors was significantly lower in Pem+Cb (17.0%) 
compared with Pac+Cb+Bev (30.1%) (p = 0.005).
Postdiscontinuation Therapies
Second-line therapy and beyond was determined by 
the treating physician. Among the ITT population, the use 
of second-line treatment was similar between the two treat-
ment arms (47.3% in Pem+Cb versus 52.5% in Pac+Cb+Bev, 
p = 0.344). Treatments were similar between the two treatment 
arms except for docetaxel (26.4% in Pem+Cb versus 6.1% in 
Pac+Cb+Bev, p < 0.001) and pemetrexed (8.8% in Pem+Cb 
versus 34.1% in Pac+Cb+Bev, p < 0.001). Other therapies 
administered to ≥5% of the patients but not significantly dif-
ferent in Pem+Cb versus Pac+Cb+Bev included: bevacizumab 
(7.7% versus 12.8%), carboplatin (9.9% versus 16.2%), erlo-
tinib (9.3% versus 7.8%), gemcitabine (5.5% versus 5.0%), 
and paclitaxel (6.0% versus 7.3%).
DISCUSSION
The randomized phase III PRONOUNCE study dem-
onstrated that Pem+Cb was not superior to Pac+Cb+Bev for 
either the primary end point of G4PFS (p = 0.176) or for the 
secondary efficacy end points of PFS, OS, ORR, and DCR. 
This trial attempted for the first time to prospectively mea-
sure the novel primary end point of G4PFS. Although G4PFS 
has not been validated, a previous clinical trial that showed 
similar survival with pemetrexed versus docetaxel13 was ret-
rospectively analyzed for OS without grade 3/4 toxicity and 
suggested a benefit-to-risk favoring pemetrexed compared 
with docetaxel in the second-line treatment of patients with 
NSCLC.26 A similar primary end point (survival without grade 
3/4 toxicity) was also used in a phase III clinical trial com-
paring pemetrexed/carboplatin with docetaxel/carboplatin as 
first-line treatment for advanced, nonsquamous NSCLC.31 
This end point (survival without grade 3/4 toxicity) also has 
been analyzed post hoc in a large phase III trial.32 The current 
study prospectively evaluated PFS without grade 4 toxicity 
and did not show superior benefit-to-risk for Pem+Cb com-
pared with Pac+Cb+Bev. Both the treatments showed similar 
severity and temporal onset of toxicity, although the specific 
toxicities differed between the arms. The G4PFS end point as 
applied here did not discriminate between different, similarly 
graded AEs that may have different significance for patient 
quality of life.30
The G4PFS end point was hoped to provide an indica-
tion of toxicity and efficacy. A substantial number of patients 
met this end point from a toxicity standpoint although still 
responding to their assigned regimen and continued on study. 
As might be expected, the majority of non-PD G4PFS end 
points occurred in the first four cycles of therapy during plati-
num doublet/triplet treatment. This provides some reassurance 
about the tolerability of maintenance with either pemetrexed 
or bevacizumab.
Regular weekly complete blood cell counts in the 
experimental setting compared with clinical practice may 
have contributed to the observed higher incidences of labo-
ratory toxicities, sometimes referred to as paper toxicities. If 
the G4PFS end point is used in future studies, consideration 
should be given to excluding nonclinically significant labora-
tory toxicities and to including some lower grade toxicities 
such as grade 2 neuropathy or alopecia, that are considered 
clinically relevant to the patients. The practice of weekly labo-
ratory testing in asymptomatic participants in clinical trials 
where this is not standard in a nonstudy population treated 
TABLE 2.  First Occurrences of G4PFS Events in Intent-to-
Treat Population
Event
Pem+Cb
N = 182
Pac+Cb+Bev
N = 179
G4PFS n = 152 (%) n = 144 (%)
  G4 events 37 (24.3) 64 (44.4)
  Progressive disease 95 (62.5) 68 (47.2)
  Death 20 (13.2) 12 (8.3)
G4 events n = 37 (%) n = 64 (%)
  Neutropenia 6 (16.2) 46 (71.9)
  Thrombocytopenia 13 (35.1) 4 (6.3)
  Thrombosis/thrombus/embolism 3 (8.1) 3 (4.7)
  Leukopenia 1 (2.7) 3 (4.7)
  Hyperglycemia 2 (5.4) 1 (1.6)
  Confusion 1 (2.7) 1 (1.6)
  Vascular access thrombosis 1 (2.7) 1 (1.6)
  Othersa 10 (27.0) 5 (8.0)
aOther isolated events include allergic reaction, cardiac ischemia, troponin T elevation, 
left ventricular dysfunction, creatinine elevation, diarrhea, muscle weakness, neurology 
nonspecific, joint pain, back pain, pericarditis, hyperkalemia, hyponatremia, renal failure.
Bev, bevacizumab; Cb, carboplatin; G4, Grade 4; Pac, paclitaxel; Pem, pemetrexed; 
PFS, progression free survival. 
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with similar regimens should be carefully considered for 
future studies.
The PFS and OS values reported here are comparable 
with other recently reported phase III trials with pemetrexed 
and platinum combinations and with other chemotherapy and 
bevacizumab combinations.11,14,21,33 Because of the small num-
ber of patients, we did not evaluate the differences in safety 
and efficacy in the >70 years age subgroup. Earlier studies 
have shown conflicting outcomes with or without differences 
by age groups.34,35 These data when analyzed will be reported 
elsewhere.
The efficacy of the control arm (Pac+Cb+Bev) in this 
study showed lower median survivals compared with previous 
trials11,21 possibly due to differences in the study populations 
and smaller sample size. The estimation of median OS in the 
control arm was 11.66 months with 95% CI (9.17–14.32), 
which is similar to the outcome in the ECOG 4599 study (12.3 
months).11
Patients experienced acceptable and expected toxicities 
on both the arms of this study based upon comparable rates 
of total AEs reported in previous pemetrexed plus platinum-
based regimens21,33 and bevacizumab combinations.11
Several AEs considered most important to patients30 
including grade 1 and 2 alopecia and sensory neuropathy 
were significantly more common with Pac+Cb+Bev than with 
Pem+Cb (p < 0.001), whereas grade 1 nausea was significantly 
more common in patients receiving Pem+Cb (p = 0.003). 
Other grades of sensory neuropathy, febrile neutropenia, 
HR (95% CI)
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Age (years): >70 (n=110)
Gender: Male (n=209)
Gender: Female (n=152)
Ethnicity: Caucasian (n=322)
Ethnicity: Non-Caucasian (n=39)
Previously treated brain metastasis: Yes (n=54)
Previously treated brain metastasis: No (n=306)
Smoking status: Ever (n=336)
Smoking status: Never (n=23)
Histologic subtype: Adenocarcinoma (n=289)
Histologic subtype: Large cell (n=10)
Histologic subtype: Other or Indeterminant (n=61)
ECOG Performance Status: 0 (n=169)
ECOG Performance Status: 1 (n=191)
Overall (n=361)
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Histologic subtype: Large cell (n=10)
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ECOG Performance Status: 0 (n=169)
ECOG Performance Status: 1 (n=191)
Overall (n=361)
Favors Pem+Cb Favors Pac+Cb+Bev
A
B
FIGURE 3. A, Subgroup analysis of 
G4 progression-free survival, and (B), 
overall survival, hazard ratio (95% 
CI). Bev, bevacizumab; Cb, carbo-
platin; ECOG, Eastern Cooperative 
Oncology Group; HR, hazard ratio; 
Pac, paclitaxel; Pem, pemetrexed; CI, 
confidence interval.
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fatigue, nausea, and vomiting were similar between the treat-
ment arms. The specific toxicity profiles and resource use dif-
fered by regimen.
In addition to the traditionally measured toxicities, 
financial burden is becoming recognized as an additional tox-
icity that may affect a patient’s potential course of treatment 
or quality of life.36–39 Using data from the PRONOUNCE trial, 
a post hoc cost analysis estimated differences in costs of treat-
ment and related patient care between the two study regimens. 
Clinical data, resource use, and postdiscontinuation therapy 
data were used to estimate preprogression and postprogres-
sion inputs to which the respective 2013 unit costs were 
applied. The costs were obtained from three sources: Truven 
Health Analytics (drug wholesale acquisition costs), Centers 
for Medicare and Medicaid Services (drug administration and 
transfusion costs), and HCUPnet (hospital charges for treat-
ing toxicities). Results suggest that the average total cost of 
treatment with Pem+Cb was $4,690 less than Pac+Cb+Bev 
($30,334 versus $35,024), and Pem+Cb was cost-saving in 
99% of 10,000 iterations of a probabilistic sensitivity analysis 
that used Monte Carlo methods.40
The recently published results for the PointBreak 
study comparing Pem+C+Bev followed by Pem+Bev to 
Pac+C+Bev followed by Bev showed no statistical difference 
in OS, though PFS was statistically longer in the pemetrexed 
arm; different toxicities were noted between the two study 
arms. Similarly, this PRONOUNCE trial that compared 
Pem+Cb followed by Pem to Pac+Cb+Bev followed by Bev 
demonstrated no significant difference of efficacy for OS and 
PFS between the treatment arms, and again different toxici-
ties were noted. Comparison of the results of these two stud-
ies are informative when choosing a chemotherapy regimen 
for a given patient who may not tolerate certain regimens and 
reassures the clinicians that the standard of care therapy is 
being offered to each patient based upon individual prefer-
ences and comorbid conditions.
In conclusion, the PRONOUNCE study objective 
of superiority of G4PFS was not met; no superiority was 
observed for the standard end points such as PFS, OS, ORR, 
or DCR in Pem+Cb compared with Pac+Cb+Bev. The safety 
profiles of both the treatment regimens are reasonable, though 
different. Differing toxicity profiles are often a deciding factor 
considered by treating oncologists when choosing an effective 
regimen for nonsquamous NSCLC.
ACKNOWLEDGMENTS
This study was funded by Eli Lilly and Company, 
Indianapolis, IN. The authors wish to thank all the patients 
and the investigators who participated in this clinical trial.
REFERENCES
 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J 
Clin 2013;63:11–30.
 2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung 
cancer: epidemiology, risk factors, treatment, and survivorship. Mayo 
Clin Proc 2008;83:584–594.
 3. Obasaju CK, Raju RN, Stinchcombe T, et al. Final results of a randomized 
phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) ver-
sus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage 
IIIB/IV non–small-cell lung cancer (NSCLC). J Clin Oncol 27:15s, 2009 
(suppl abstract 8037).
 4. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-
small-cell lung cancer: how much benefit is enough? J Clin Oncol 
1993;11:1866–1872.
 5. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. 
Chemotherapy vs supportive care in advanced non-small-cell lung cancer. 
Results of a meta-analysis of the literature. Chest 1994;106:861–865.
 6. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced 
non small cell lung cancer: a meta-analysis. Lancet 1993;342:19–21.
 7. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II 
study of taxol, merbarone, and piroxantrone in stage IV non-small-cell 
lung cancer: the Eastern Cooperative Oncology Group results. J Natl 
Cancer Inst 1993;85:388–392.
 8. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in 
patients with untreated advanced non-small-cell lung cancer. J Natl 
Cancer Inst 1993;85:384–388.
 9. Scagliotti GV, De Marinis F, Rinaldi M, et al; Italian Lung Cancer Project. 
Phase III randomized trial comparing three platinum-based doublets in 
advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285–4291.
 10. Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology 
Group. Comparison of four chemotherapy regimens for advanced non-
small-cell lung cancer. N Engl J Med 2002;346:92–98.
 11. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone 
or with bevacizumab for non-small-cell lung cancer. N Engl J Med 
2006;355:2542–2550.
TABLE 3.  Drug-Related Grade 3 and 4 Common Terminology Criteria for Adverse Events in Patients (Safety Population)
Event
Grade 3 AEs Grade 4 AEs
Pem+Cb 
N = 171
n (%)
Pac+Cb+Bev 
N = 166
n (%) p Value
Pem+Cb 
N = 171
n (%)
Pac+Cb+Bev 
N = 166
n (%) p Value
Anemia 31 (18.1) 9 (5.4) < 0.001 1 (0.6) 0 (0.0) 1.000
Neutropenia 36 (21.1) 37 (22.3) 0.793 6 (3.5) 44 (26.5) < 0.001
Thrombocytopenia 26 (15.2) 7 (4.2) < 0.001 15 (8.8) 9 (5.4) 0.291
Febrile neutropenia 0 (0.0) 2 (1.2) 0.242 0 (0.0) 1 (0.6) 0.493
Hypertension 0 (0.0) 4 (2.4) 0.058 0 (0.0) 0 (0.0) N/A
Thrombosis/embolism 0 (0.0) 3 (1.8) 0.118 0 (0.0) 1 (0.6) 0.493
Any hemorrhagic events 2 (1.2) 0 (0.0) 0.499 0 (0.0) 0 (0.0) N/A
Sensory neuropathy 0 (0.0) 4 (2.4) 0.058 0 (0.0) 0 (0.0) N/A
Grade 5 AEs: One death (neutropenia) in Pem+Cb and two deaths (myocardial infarction and pulmonary embolism) in Pac+Cb+Bev occurred.
AEs, adverse events; Bev, bevacizumab; Cb, carboplatin; N/A, not available; Pac, paclitaxel; Pem, pemetrexed.
142 Copyright © 2014 by the International Association for the Study of Lung Cancer
Zinner et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015
 12. Somer RA, Sherman E, Langer CJ. Restrictive eligibility limits access to 
newer therapies in non-small-cell lung cancer: the implications of Eastern 
Cooperative Oncology Group 4599. Clin Lung Cancer 2008;9:102–105.
 13. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of 
pemetrexed versus docetaxel in patients with non-small-cell lung cancer 
previously treated with chemotherapy. J Clin Oncol 2004;22:1589–1597.
 14. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing 
cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemother-
apy-naive patients with advanced-stage non-small-cell lung cancer. J Clin 
Oncol 2008;26:3543–3551.
 15. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus 
best supportive care versus placebo plus best supportive care for non-
small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 
2009;374:1432–1440.
 16. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall 
survival results of the phase III study of maintenance pemetrexed ver-
sus placebo immediately after induction treatment with pemetrexed plus 
cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin 
Oncol 2013;31:2895–2902.
 17. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of peme-
trexed according to NSCLC histology: a review of two Phase III studies. 
Oncologist 2009;14:253–263.
 18. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in ade-
nocarcinoma and large cell lung cancer than in squamous cell carcinoma? 
A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel 
in previously treated patients with advanced non-small cell lung cancer 
(NSCLC). J Thorac Oncol 2007;2:s851.
 19. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed 
in combination with carboplatin in the first-line treatment of advanced 
nonsmall cell lung cancer. Cancer 2005;104:2449–2456.
 20. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with 
oxaliplatin or carboplatin as first-line treatment in advanced non-small 
cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer 
Res 2005;11(2 Pt 1):690–696.
 21. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase 
III study of pemetrexed plus carboplatin and bevacizumab followed by 
maintenance pemetrexed and bevacizumab versus paclitaxel plus car-
boplatin and bevacizumab followed by maintenance bevacizumab in 
patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. 
J Clin Oncol 2013;31:4349–4357.
 22. Smith IE, O’Brien ME, Talbot DC, et al. Duration of chemotherapy in 
advanced non-small-cell lung cancer: a randomized trial of three ver-
sus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 
2001;19:1336–1343.
 23. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a 
defined duration of therapy versus continuous therapy followed by sec-
ond-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. 
J Clin Oncol 2002;20:1335–1343.
 24. Socinski MA, Stinchcombe TE. Duration of first-line chemotherapy in 
advanced non small-cell lung cancer: less is more in the era of effective 
subsequent therapies. J Clin Oncol 2007;25:5155–5157.
 25. Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in 
advanced non-small cell lung cancer. Curr Treat Options Oncol 
2007;8:38–46.
 26. Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity 
criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in 
previously treated patients with advanced non-small cell lung cancer 
(NSCLC): a risk-benefit analysis. J Thorac Oncol 2007;2:397–401.
 27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the 
response to treatment in solid tumors. European Organization for Research 
and Treatment of Cancer, National Cancer Institute of the United States, 
National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.
 28. [NCI] National Cancer Institute. Common Terminology Criteria for 
Adverse Events v3.0 (CTCAE), 2006; available from http://ctep.can-
cer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.
pdf;Internet; accessed 22 Apr. 2014.
 29. Zinner RG, Saxman SB, Peng G, Monberg MJ, Ortuzar WI. Treatment 
rationale and study design for a randomized trial of pemetrexed/carbo-
platin followed by maintenance pemetrexed versus paclitaxel/carbopla-
tin/bevacizumab followed by maintenance bevacizumab in patients with 
advanced non-small-cell lung cancer of nonsquamous histology. Clin 
Lung Cancer 2010;11:352–357.
 30. Dubey S, Brown RL, Esmond SL, Bowers BJ, Healy JM, Schiller JH. 
Patient preferences in choosing chemotherapy regimens for advanced 
non-small cell lung cancer. J Support Oncol 2005;3:149–154.
 31. Rodrigues-Pereira J, Kim JH, Magallanes M, et al. A randomized phase 
3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as 
first-line treatment for advanced, nonsquamous non-small cell lung can-
cer. J Thorac Oncol 2011;6:1907–1914.
 32. Scagliotti GV, Park K, Patil S, et al. Survival without toxicity for cis-
platin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve 
patients with advanced non-small cell lung cancer: a risk-benefit analysis 
of a large phase III study. Eur J Cancer 2009;45:2298–2303.
 33. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus 
gemcitabine with either placebo or bevacizumab as first-line therapy 
for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 
2009;27:1227–1234.
 34. Ramalingam SS, Dahlberg SE, Langer CJ, et al; Eastern Cooperative 
Oncology Group. Outcomes for elderly, advanced-stage non small-cell 
lung cancer patients treated with bevacizumab in combination with car-
boplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group 
Trial 4599. J Clin Oncol 2008;26:60–65.
 35. Langer CJ, Socinski MA, Patel JD, et al. Efficacy and safety of paclitaxel 
and carboplatin with bevacizumab for the first-line treatment of patients 
with nonsquamous non-small cell lung cancer (NSCLC): analyses based 
on age in the phase 3 PointBreak and E4599 trials [IASLC abstract 
MO06.12]. J Thorac Oncol 2013;8(suppl 2):S291.
 36. Wong YN, Egleston BL, Sachdeva K, et al. Cancer patients’ trade-offs 
among efficacy, toxicity, and out-of-pocket cost in the curative and non-
curative setting. Med Care 2013;51:838–845.
 37. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer 
treatment: a pilot study assessing out-of-pocket expenses and the insured 
cancer patient’s experience. Oncologist 2013;18:381–390.
 38. Zafar SY, Abernethy AP. Financial toxicity, part I: a new name for a growing 
problem; Available at: http://www.cancernetwork.com/practice-policy/finan-
cial-toxicity-part-i-new-name-growing-problem. Accessed April 22, 2014.
 39. Zafar SY, Abernethy AP. Financial toxicity, part II: how can we help with the 
burden of treatment-related costs? Available at: http://www.cancernetwork. 
com/practice-policy/financial-toxicity-part-ii-how-can-we-helpburden-treat-
ment-related-costs. Accessed April 22, 2014.
 40. Graham CN, Knox H, Winfree KB, et al. Cost-minimization analysis 
of pemetrexed/carboplatin with maintenance pemetrexed (PemC) ver-
sus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab 
(PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC). ASCO 
Quality Care Symposium 2013 (abstr 263).
